{
  "pmcid": "9351589",
  "sha256": "8aa6d39d130426a7337e1f2b29cdce01409e0d077d881ca989bc5a503551deaa",
  "timestamp_utc": "2025-11-10T00:12:22.805943+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.603190789473683,
    "reading_ease": 43.59952302631581,
    "word_count": 285
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Panitumumab Addition to Hepatic Arterial Infusion and Systemic Chemotherapy in RAS Wild-Type Colorectal Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "phase II randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible patients with resected colorectal liver metastases (CRLM) and K RAS wild-type"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive HAI FUDR + SYS FOLFIRI with or without Pmab"
      },
      "Objective": {
        "score": 1,
        "evidence": "assessed whether adding panitumumab (Pmab) to an adjuvant regimen of hepatic arterial infusion (HAI) of floxuridine (FUDR) plus systemic leucovorin, fluorouracil, and irinotecan (FOLFIRI) improves 15-month recurrence-free survival (RFS)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was 15-month RFS"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding details were not provided"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Seventy-five patients were randomised, with 38 in the Pmab arm and 37 in the control arm"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "At 15 months, 25 patients (69%; 95% CI, 53 to 82) in the Pmab arm and 18 patients (47%; 95% CI, 32 to 63) in the control arm were alive and recurrence-free"
      },
      "Harms": {
        "score": 1,
        "evidence": "Rash was more frequent in the Pmab arm, but grade 3/4 elevations in bilirubin or alkaline phosphatase were similar between groups"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered under NCT01312857"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}